Literature DB >> 16869343

Non-erosive reflux disease and atypical gastro-oesophageal reflux disease manifestations: treatment results.

Jean Paul Galmiche1.   

Abstract

Gastro-oesophageal reflux disease (GERD) is a widespread complex disorder that may be responsible for a variety of different symptoms and clinical features. Despite the presence of symptoms, the majority of patients do not have endoscopic lesions of oesophagitis. Non-erosive reflux disease (NERD) is a chronic, relapsing condition that can adversely affect the quality of life despite the absence of mucosal breaks at endoscopy. In many patients GERD is associated with extra-oesophageal or atypical manifestations, including cough, asthma, laryngitis or non-cardiac chest pain. Acid suppression with proton pump inhibitors (PPI) remains the mainstay of GERD therapy. However, patients with NERD and extra-oesophageal manifestations are often poorly responsive to PPI therapy. Accurate diagnosis followed by adequate PPI dosage and compliance with therapy are essential for the successful control of NERD and extra-oesophageal manifestations. The better detection and characterization of acid and non-acid reflux episodes using developing technologies, such as combined pH-impedance monitoring, is extending our understanding of the pathophysiology of NERD and the extra-oesophageal manifestations of GERD, and will lead to the improved management of these often poorly responsive conditions. This article reviews the treatment results and outlines approaches to the evaluation, diagnosis and therapy of NERD and atypical GERD manifestations.

Entities:  

Mesh:

Year:  2006        PMID: 16869343     DOI: 10.2165/00003495-200666001-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  21 in total

1.  An evidence-based appraisal of reflux disease management--the Genval Workshop Report.

Authors: 
Journal:  Gut       Date:  1999-04       Impact factor: 23.059

2.  Does medical antireflux therapy improve asthma in asthmatics with gastroesophageal reflux?: a critical review of the literature.

Authors:  S K Field; L R Sutherland
Journal:  Chest       Date:  1998-07       Impact factor: 9.410

3.  Chronic cough and gastro-oesophageal reflux: a double-blind placebo-controlled study with omeprazole.

Authors:  T O Kiljander; E R Salomaa; E K Hietanen; E O Terho
Journal:  Eur Respir J       Date:  2000-10       Impact factor: 16.671

Review 4.  Is proton pump inhibitor testing an effective approach to diagnose gastroesophageal reflux disease in patients with noncardiac chest pain?: a meta-analysis.

Authors:  Wei Hong Wang; Jia Qing Huang; Ge Fan Zheng; Wai Man Wong; Shiu Kum Lam; Johan Karlberg; Harry H X Xia; Ronnie Fass; Benjamin C Y Wong
Journal:  Arch Intern Med       Date:  2005-06-13

5.  Weakly acidic reflux in patients with chronic unexplained cough during 24 hour pressure, pH, and impedance monitoring.

Authors:  D Sifrim; L Dupont; K Blondeau; X Zhang; J Tack; J Janssens
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

Review 6.  Review of the quality of life and burden of illness in gastroesophageal reflux disease.

Authors:  Ingela Wiklund
Journal:  Dig Dis       Date:  2004       Impact factor: 2.404

Review 7.  Effectiveness of proton pump inhibitors in nonerosive reflux disease.

Authors:  Bonnie B Dean; Anacleto D Gano; Kevin Knight; Joshua J Ofman; Ronnie Fass
Journal:  Clin Gastroenterol Hepatol       Date:  2004-08       Impact factor: 11.382

Review 8.  Ear, nose and throat and respiratory manifestations of gastro-esophageal reflux disease: an increasing conundrum.

Authors:  Joel E Richter
Journal:  Eur J Gastroenterol Hepatol       Date:  2004-09       Impact factor: 2.566

9.  The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain.

Authors:  R Fass; M B Fennerty; J J Ofman; I M Gralnek; C Johnson; E Camargo; R E Sampliner
Journal:  Gastroenterology       Date:  1998-07       Impact factor: 22.682

10.  Prevalence of extra-oesophageal manifestations in gastro-oesophageal reflux disease: an analysis based on the ProGERD Study.

Authors:  D Jaspersen; M Kulig; J Labenz; A Leodolter; T Lind; W Meyer-Sabellek; M Vieth; S N Willich; D Lindner; M Stolte; P Malfertheiner
Journal:  Aliment Pharmacol Ther       Date:  2003-06-15       Impact factor: 8.171

View more
  7 in total

1.  Therapeutic management of uncomplicated gastroesophageal reflux disease in france in 2005: Potential cost savings of omeprazole substitution.

Authors:  Stéphane Mouly; Agnès Charlemagne; Philippe Lejeunne; Francis Fagnani
Journal:  Curr Ther Res Clin Exp       Date:  2009-08

2.  Acid-suppressive effect of rabeprazole 5 mg and 10 mg once daily by 24-hour esophageal pH monitoring in patients with non-erosive reflux disease in Japan: a multicenter, randomized, parallel-group, double-blind pharmacodynamic study.

Authors:  Kiyoshi Ashida; Yoshikazu Kinoshita; Michio Hongo
Journal:  Dig Dis Sci       Date:  2011-02-08       Impact factor: 3.199

3.  Anxiety and depression in patients with gastroesophageal reflux disease and their effect on quality of life.

Authors:  Xiao-Jun Yang; Hong-Mei Jiang; Xiao-Hua Hou; Jun Song
Journal:  World J Gastroenterol       Date:  2015-04-14       Impact factor: 5.742

4.  A randomized open-label trial of on-demand rabeprazole vs ranitidine for patients with non-erosive reflux disease.

Authors:  Abdallah A Kobeissy; Jana G Hashash; Faek R Jamali; Assaad M Skoury; Reham Haddad; Sarah El-Samad; Rami Ladki; Rola Aswad; Assaad M Soweid
Journal:  World J Gastroenterol       Date:  2012-05-21       Impact factor: 5.742

5.  Prevalence, risk factors, and healthcare-seeking among subjects with esophageal symptoms: A community-based study in a rural Bangladeshi population.

Authors:  M Masudur Rahman; Uday C Ghoshal; Md Golam Kibria; Nigar Sultana; Faruque Ahmed; Ahm Rowshon; Mahmud Hasan
Journal:  JGH Open       Date:  2020-09-22

6.  Outcomes in patients with nonerosive reflux disease treated with a proton pump inhibitor and alginic acid ± glycyrrhetinic acid and anthocyanosides.

Authors:  Francesco Di Pierro; Mario Gatti; Giuliana Rapacioli; Leandro Ivaldi
Journal:  Clin Exp Gastroenterol       Date:  2013-03-27

7.  Gastroesophageal Reflux Disease Associated With Anxiety: Efficacy and Safety of Fixed Dose Combination of Amitriptyline and Pantoprazole.

Authors:  Arif A Faruqui
Journal:  Gastroenterology Res       Date:  2017-10-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.